Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd has experienced a notable shift in price momentum, with technical indicators signalling a transition from mildly bearish to bearish trends. Despite a marginal day gain of 0.12%, the stock’s broader technical landscape suggests caution for investors amid weakening momentum and mixed signals from key oscillators and moving averages.

Astrazeneca Pharma India Ltd has seen its investment rating downgraded from Hold to Sell as of 2 January 2026, reflecting a shift in technical indicators and valuation metrics despite solid financial performance. The downgrade is primarily driven by a deteriorating technical trend, expensive valuation multiples, and mixed signals from financial and quality parameters, signalling caution for investors in the Pharmaceuticals & Biotechnology sector.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of early January 2026. This transition is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling a cautious outlook for investors amid recent price declines and mixed market signals.

Astrazeneca Pharma India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend as of late December 2025. Despite a year-to-date return of 21.3%, outperforming the Sensex by a wide margin, recent technical indicators suggest a more cautious outlook for investors as mixed signals emerge across key momentum and trend metrics.

Astrazeneca Phar has undergone a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. This adjustment comes amid a backdrop of strong profitability metrics and premium valuation levels within the Pharmaceuticals & Biotechnology sector.

Astrazeneca Phar has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a blend of strong operational fundamentals alongside valuation concerns, prompting a reassessment of its standing within the Pharmaceuticals & Biotechnology sector.

Astrazeneca Pharma India has recently experienced a change in its evaluation, influenced by shifts in technical indicators. The company has shown strong financial performance, with a year-to-date return of 23.77% and a notable profit growth of 35.70% in the last six months, outperforming the BSE500 index consistently.

AstraZeneca Pharma India has recently revised its evaluation amid current market dynamics, with its stock priced at 9,078.70. Over the past year, it has achieved a return of 20.97%, significantly outperforming the Sensex. The technical outlook presents mixed signals, indicating cautious optimism in its performance.

AstraZeneca Pharma India Ltd. delivered a mixed performance in Q2 FY26, with robust revenue expansion overshadowed by margin compression and a sequential decline in profitability. The pharmaceutical major reported net sales of ₹526.31 crores for the quarter ended June 2025, marking a healthy 9.54% quarter-on-quarter increase and an impressive 35.81% year-on-year surge. However, net profit stood at ₹55.83 crores, declining 4.15% sequentially from ₹58.25 crores in Q1 FY26, though still recovering substantially from the loss of ₹11.79 crores recorded in the corresponding quarter last year.